International Journal of Clinical Oncology

, Volume 16, Issue 4, pp 285–286 | Cite as

Primary lung cancer in never smokers

  • Yoshihiko MaeharaEmail author
Introduction to Review Articles


Lung Cancer Epidermal Growth Factor Receptor Gefitinib Tyrosine Kinase Inhibitor Cancer Death Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Jemal A, Siegel R, Xu J et al (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300PubMedCrossRefGoogle Scholar
  2. 2.
    Wakelee HA, Chang ET, Gomez SL et al (2007) Lung cancer incidence in never smokers. J Clin Oncol 25:472–478PubMedCrossRefGoogle Scholar
  3. 3.
    Subramanian J, Govindan R (2007) Lung cancer in never smokers: a review. J Clin Oncol 25:561–570PubMedCrossRefGoogle Scholar
  4. 4.
    Yano T, Miura N, Takenaka T et al (2008) Never-smoking non-small cell lung cancer as a separate entity—the clinico-pathologic features and survival. Cancer 113:1012–1018PubMedCrossRefGoogle Scholar
  5. 5.
    Mok TS, Wu YL, Thongprasent S et al (2009) Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957PubMedCrossRefGoogle Scholar
  6. 6.
    Shaw AT, Yeap BY, Mino-Kenudson M et al (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247–4253PubMedCrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2011

Authors and Affiliations

  1. 1.Department of Surgery and Science, Graduate School of Medical SciencesKyushu UniversityFukuoka CityJapan

Personalised recommendations